AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Completed · Phase 2
Conditions studied: Advanced Breast Cancer
In brief
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.
Key facts
- Study ID
- NCT00454805
- Run by
- AstraZeneca
- People needed
- 75
- Starts
- 2007-03-01
- Expected to finish
- 2016-04-01
- Last updated by the study team
- 2016-08-03
Who can join
Age: 18 and older, up to 130. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Written informed consent
- Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease
- One or more evaluable lesions
You may not qualify if…
- Prior hormonal therapy with fulvestrant
- More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer
- Prior biologic therapy for ABC including Anti-VEGF agents
- Radiation therapy within 4 weeks prior to provision of consent
Where it is running
- Research Site — Burbank, California, United States
- Research Site — Los Angeles, California, United States
- Research Site — Palm Springs, California, United States
- Research Site — Boca Raton, Florida, United States
- Research Site — Honolulu, Hawaii, United States
- Research Site — New York, New York, United States
- Research Site — Fitzroy, Australia
- Research Site — Parkville, Australia
- Research Site — Perth, Australia
- Research Site — Waratah, Australia
- Research Site — Belo Horizonte, Brazil
- Research Site — Curitiba, Brazil
- Research Site — Fortaleza, Brazil
- Research Site — Porto Alegre, Brazil
- Research Site — Santro Andre, Brazil
- Research Site — São Paulo, Brazil
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.